TIL

Instil Bio's stock price has experienced significant volatility and decline. Key events include the discontinuation of lead clinical programs in January 2026, which caused shares to slide. Investor alerts and investigations by law firms were announced on behalf of investors in January and February 2026. On March 27, 2026, the company reported its fourth quarter and full year 2025 financial results, ending 2025 with $76.3 million in cash and expecting this to fund operations beyond 2027. As of April 23, 2026, the share price was $8.18, a 58.29% decline from the previous year.